Document
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. DEVA HOLDING A.S., 2:24-cv-04404, No. 23 (D.N.J. Aug. 5, 2024)
This matter comes before the Court on the motion to dismiss by Defendant Deva Holding A.S.
The statute, 35 U.S.C. § 271(e) (emphasis added), states: (2) It shall be an act of infringement to submit— (A) an application under section 505(j) of the Federal Food, Drug, and Cosmetic Act [21 USCS § 355(j)] or described in section 505(b)(2) of such Act [21 USCS § 355(b)(2)] for a drug claimed in a patent or the use of which is claimed in a patent ...
The parties shall file supplementary briefs on this question: what is the definition of “drug” in the context of this statutory provision?
Briefs shall be no longer than three pages and shall be submitted simultaneously by August 19, 2024.
Cite Document
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. DEVA HOLDING A.S., 2:24-cv-04404, No. 23 (D.N.J. Aug. 5, 2024)
+ More Snippets
Document
EBIN NEW YORK, INC. v. KISS NAIL PRODUCTS, INC. et al, 2:23-cv-02369, No. 49 (D.N.J. Mar. 28, 2024)
None of the conditions warranting dismissal with prejudice are present here.
Cite Document
EBIN NEW YORK, INC. v. KISS NAIL PRODUCTS, INC. et al, 2:23-cv-02369, No. 49 (D.N.J. Mar. 28, 2024)
+ More Snippets
Document
GW RESEARCH LIMITED v. TEVA PHARMACEUTICALS, INC. et al, 2:23-cv-00018, No. 252 (D.N.J. Jan. 11, 2024)
v. Becton, Dickinson & Co., 649 F.3d 1276, 1285 (Fed. Cir. 2011) (en banc) (“Tnequitable conduct is an equitable defense to patent infringement that, if proved, bars enforcement of a patent.”).> D. The Motion The Plaintiff, as noted, moved to dismiss the Counterclaim.
In the 2007 Agreement, the Plaintiff and that entity agreed to collaborate, “with a view to selecting the most promising candidates for full clinical development[.
To see why, begin by noting that to establish intent for inequitable conduct purposes, a claimant must “name the specific individual associated with the filing or prosecution of the application issuing ... who both knew of the material information and deliberately withheld or misrepresented it.” Exergen, 975 F.3d at 1329.
July 30, 2013) {intent not properly pled because the complaint failed to allege “the specific individual who knew that [the patent applicant] did not qualify as a small entity and made the misrepresentation to the PTO”) (cleaned up); Int’l Test Sols., Inc. v. Mipox Int’l Corp., 2017 WL 2118314, at *6 (N.D. Cal.
The Defendants would have the the Counterclaim fails because it did not plead, as it In sum: the “name fof] the specific individual associated with had to, the filing or prosecution of the application issuing ... who both knew of the material information and deliberately withheld or misrepresented it.” Exergen, 575 F.3d at 1329.4
Cite Document
GW RESEARCH LIMITED v. TEVA PHARMACEUTICALS, INC. et al, 2:23-cv-00018, No. 252 (D.N.J. Jan. 11, 2024)
+ More Snippets
Document
NOVAPLAST CORPORATION v. INPLANT, LLC et al, 2:20-cv-07396, No. 73 (D.N.J. Jul. 26, 2023)
Cite Document
NOVAPLAST CORPORATION v. INPLANT, LLC et al, 2:20-cv-07396, No. 73 (D.N.J. Jul. 26, 2023)
+ More Snippets
Document
DAYS INNS WORLDWIDE, INC. v. AVST HOSPITALITY, LLC et al, 2:22-cv-01935, No. 24 (D.N.J. Jul. 10, 2023)
Cite Document
DAYS INNS WORLDWIDE, INC. v. AVST HOSPITALITY, LLC et al, 2:22-cv-01935, No. 24 (D.N.J. Jul. 10, 2023)
+ More Snippets
Document
CURELIFE CO., LTD. et al v. IDEAVILLAGE PRODUCTS CORP., 2:24-cv-10910, No. 1 (D.N.J. Dec. 4, 2024)
Complaint
Cite Document
CURELIFE CO., LTD. et al v. IDEAVILLAGE PRODUCTS CORP., 2:24-cv-10910, No. 1 (D.N.J. Dec. 4, 2024)
+ More Snippets
Document
INCYTE CORPORATION et al v. SUN PHARMACEUTICAL INDUSTRIES LTD. et al, 2:24-cv-06944, No. 126 (D.N.J. Oct. 22, 2024)
Motion to Seal
Cite Document
INCYTE CORPORATION et al v. SUN PHARMACEUTICAL INDUSTRIES LTD. et al, 2:24-cv-06944, No. 126 (D.N.J. Oct. 22, 2024)
+ More Snippets
Document
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. DEVA HOLDING A.S., 2:24-cv-04404, No. 37 (D.N.J. Sep. 18, 2024)
Motion to Extend Time
Cite Document
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. DEVA HOLDING A.S., 2:24-cv-04404, No. 37 (D.N.J. Sep. 18, 2024)
+ More Snippets
Document
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. DEVA HOLDING A.S., 2:24-cv-04404, No. 36 (D.N.J. Sep. 11, 2024)
Cite Document
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. DEVA HOLDING A.S., 2:24-cv-04404, No. 36 (D.N.J. Sep. 11, 2024)
+ More Snippets
Document
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. DEVA HOLDING A.S., 2:24-cv-04404, No. 25 (D.N.J. Aug. 19, 2024)
Cite Document
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. DEVA HOLDING A.S., 2:24-cv-04404, No. 25 (D.N.J. Aug. 19, 2024)
+ More Snippets
Document
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. DEVA HOLDING A.S., 2:24-cv-04404, No. 60 (D.N.J. Mar. 6, 2025)
Cite Document
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. DEVA HOLDING A.S., 2:24-cv-04404, No. 60 (D.N.J. Mar. 6, 2025)
+ More Snippets
Document
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. DEVA HOLDING A.S., 2:24-cv-04404, No. 58 (D.N.J. Mar. 5, 2025)
Cite Document
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. DEVA HOLDING A.S., 2:24-cv-04404, No. 58 (D.N.J. Mar. 5, 2025)
+ More Snippets
Document
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. DEVA HOLDING A.S., 2:24-cv-04404, No. 57 (D.N.J. Feb. 21, 2025)
Cite Document
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. DEVA HOLDING A.S., 2:24-cv-04404, No. 57 (D.N.J. Feb. 21, 2025)
+ More Snippets
Document
INCYTE CORPORATION et al v. SUN PHARMACEUTICAL INDUSTRIES LTD. et al, 2:24-cv-06944, No. 1 (D.N.J. Jun. 11, 2024)
Cite Document
INCYTE CORPORATION et al v. SUN PHARMACEUTICAL INDUSTRIES LTD. et al, 2:24-cv-06944, No. 1 (D.N.J. Jun. 11, 2024)
+ More Snippets
Document
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. DEVA HOLDING A.S., 2:24-cv-04404, No. 56 (D.N.J. Feb. 11, 2025)
Cite Document
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. DEVA HOLDING A.S., 2:24-cv-04404, No. 56 (D.N.J. Feb. 11, 2025)
+ More Snippets